<?xml version="1.0" encoding="UTF-8"?>
<!--generator='jetpack-16.2'-->
<!--Jetpack_Sitemap_Buffer_News_XMLWriter-->
<?xml-stylesheet type="text/xsl" href="//medicinacardiometabolica.com/news-sitemap.xsl"?>
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.sitemaps.org/schemas/sitemap/0.9 http://www.sitemaps.org/schemas/sitemap/0.9/sitemap.xsd">
 <url>
  <loc>https://medicinacardiometabolica.com/2026/09/14/modificadores-riesgo-cardiovascular-2026-reclasifican-riesgo-intermedio/</loc>
  <lastmod>2026-09-14T11:26:58Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Medicina Cardiometabólica</news:name>
    <news:language>es</news:language>
   </news:publication>
   <news:title>Modificadores de riesgo cardiovascular 2026 ACC/AHA: cuáles reclasifican al paciente de riesgo intermedio y cuáles no</news:title>
   <news:publication_date>2026-09-14T11:26:58Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://medicinacardiometabolica.com/2026/09/14/mbe-semana-09-estudio-de-cohorte/</loc>
  <lastmod>2026-09-14T11:26:45Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Medicina Cardiometabólica</news:name>
    <news:language>es</news:language>
   </news:publication>
   <news:title>Estudio de Cohorte: Prospectiva, Retrospectiva y el Seguimiento</news:title>
   <news:publication_date>2026-09-14T11:26:45Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://medicinacardiometabolica.com/2026/09/13/colapso-prominente-constriccion-taponamiento/</loc>
  <lastmod>2026-09-13T22:00:00Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Medicina Cardiometabólica</news:name>
    <news:language>es</news:language>
   </news:publication>
   <news:title>Colapso y prominente: constricción versus taponamiento</news:title>
   <news:publication_date>2026-09-13T22:00:00Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://medicinacardiometabolica.com/2026/09/13/eeuu-256-levotiroxina-marca-vs-generica/</loc>
  <lastmod>2026-09-13T16:20:49Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Medicina Cardiometabólica</news:name>
    <news:language>es</news:language>
   </news:publication>
   <news:title>Levotiroxina de marca vs levotiroxina genérica: cuál es mejor, dosis, efectos secundarios y precio (2026)</news:title>
   <news:publication_date>2026-09-13T16:20:49Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://medicinacardiometabolica.com/2026/09/13/cribado-diabetes-tipo-1-radar/</loc>
  <lastmod>2026-09-13T11:35:56Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Medicina Cardiometabólica</news:name>
    <news:language>es</news:language>
   </news:publication>
   <news:title>Cribado de diabetes tipo 1: Radar cardiometabólico 13 sep</news:title>
   <news:publication_date>2026-09-13T11:35:56Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://medicinacardiometabolica.com/2026/09/13/colchicina-prevencion-cardiovascular-2026-dosis-acc-aha-esc-contraindicaciones/</loc>
  <lastmod>2026-09-13T11:17:18Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Medicina Cardiometabólica</news:name>
    <news:language>es</news:language>
   </news:publication>
   <news:title>Colchicina en prevención cardiovascular 2026: dosis de 0,5 mg, qué recomiendan ACC/AHA y ESC, y contraindicaciones absolutas</news:title>
   <news:publication_date>2026-09-13T11:17:18Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://medicinacardiometabolica.com/2026/09/12/reflujo-hepatoyugular-tecnica-rendimiento/</loc>
  <lastmod>2026-09-12T22:10:50Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Medicina Cardiometabólica</news:name>
    <news:language>es</news:language>
   </news:publication>
   <news:title>Reflujo hepatoyugular: técnica y rendimiento diagnóstico</news:title>
   <news:publication_date>2026-09-12T22:10:50Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://medicinacardiometabolica.com/2026/09/12/eeuu-255-naproxeno-para-que-sirve/</loc>
  <lastmod>2026-09-12T16:16:13Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Medicina Cardiometabólica</news:name>
    <news:language>es</news:language>
   </news:publication>
   <news:title>Naproxeno (Aleve, Flanax): para qué sirve, dosis, efectos secundarios y precio (2026)</news:title>
   <news:publication_date>2026-09-12T16:16:13Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://medicinacardiometabolica.com/2026/09/12/podcast-semanal-semiologia-vascular-riesgo-cardiometabolico-2026-09-12/</loc>
  <lastmod>2026-09-12T11:52:34Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Medicina Cardiometabólica</news:name>
    <news:language>es</news:language>
   </news:publication>
   <news:title>Podcast semanal: semiología vascular, estatinas y riesgo residual, urgencias metabólicas y fármacos de guardia</news:title>
   <news:publication_date>2026-09-12T11:52:34Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
 <url>
  <loc>https://medicinacardiometabolica.com/2026/09/12/pcr-ultrasensible-cuando-solicitarla-punto-corte-2-mg-l-acc-aha-2026/</loc>
  <lastmod>2026-09-12T11:15:17Z</lastmod>
  <news:news>
   <news:publication>
    <news:name>Medicina Cardiometabólica</news:name>
    <news:language>es</news:language>
   </news:publication>
   <news:title>PCR ultrasensible: cuándo solicitarla, punto de corte de 2 mg/L y qué decisión terapéutica cambia según ACC/AHA 2026</news:title>
   <news:publication_date>2026-09-12T11:15:17Z</news:publication_date>
   <news:genres>Blog</news:genres>
  </news:news>
 </url>
</urlset>
